Company Overview
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
Recent Developments
- Dec 2025 Revenue of $3.57M (+32.9% YoY); net profit $-7.80M.
- Trailing 12 Months Year-on-year growth — revenue +115.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.96% |
| 1 Year: | 115.70% |
Stock Price Performance
| 1 Year: | +140.24% |
| 6 Months: | +2.78% |
| 3 Months: | -11.39% |
| 1 Month: | -16.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 32.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NRXS NeurAxis, Inc. PHARMA | 5.91 | -7.78 | $74.22M | 0.00% | - | -139.76% | 9.96% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 682.58K | 618.80K | 805.11K | 646.02K | 477.46K | 646.63K | 611.50K | 666.62K | - | 895.65K | 894.09K | 811.41K | 968.13K | 1.61M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 139.47K | 146.64K | 135.49K | 141.65K | 218.37K |
| Gross Profit | - | 603.57K | 551.17K | 709.21K | 578.21K | 410.17K | 571.55K | 538.04K | 569.58K | - | 756.18K | 747.44K | 675.93K | 826.48K | 1.39M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 3.05M | 2.47M | 2.78M | 2.54M | 3.13M |
| Operating Income | - | -669.58K | -1.20M | -896.27K | -1.12M | -3.02M | -1.83M | -2.21M | -1.65M | - | -2.30M | -1.72M | -2.10M | -1.72M | -1.74M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -2.27M | -1.66M | -2.08M | -1.66M | -1.72M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 2.24K | 13.43K | 29.66K | 28.64K | 26.19K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -2.28M | -1.69M | -2.12M | -1.71M | -1.76M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.17M | -1.52M | -2.08M | -2.17M | -2.24M | -8.63M | -2.12M | -2.92M | -1.76M | - | -2.28M | -1.69M | -2.12M | -1.71M | -1.76M |
| Diluted EPS | - | -0.87 | -1.14 | -1.18 | -1.21 | -2.38 | -0.32 | -0.42 | -0.25 | - | -0.33 | -0.22 | -0.24 | - | -0.18 |
| R&D Expense | - | 13.66K | 86.17K | 16.80K | 109.79K | 44.95K | 5.57K | 54.31K | 126.25K | - | 117.87K | 58.32K | 130.85K | - | 99.57K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 2.68M | 2.46M | 2.69M | 3.57M |
| Cost of Revenue | - | 297.06K | 303.35K | 362.00K | 562.92K |
| Gross Profit | - | 2.39M | 2.16M | 2.32M | 3.01M |
| Operating Expenses | - | 5.76M | 8.82M | 9.48M | 10.84M |
| Operating Income | - | -3.37M | -6.66M | -7.16M | -7.83M |
| EBITDA | - | -4.33M | -9.23M | -7.90M | -7.67M |
| Interest Expense | - | 417.60K | 5.36M | 300.71K | 73.97K |
| Pretax Income | - | -4.78M | -14.63M | -8.24M | -7.80M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -4.78M | -14.63M | -8.24M | -7.80M |
| Diluted EPS | - | -0.90 | -2.25 | -1.22 | -0.95 |
| R&D Expense | - | 225.61K | 169.31K | 433.61K | 493.61K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Sep 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 1.48M | 1.24M | 509.50K | 4.76M | 6.40M |
| Current Assets | - | 476.96K | - | 242.61K | 4.27M | 5.73M |
| Cash & Equivalents | - | 253.70K | 761.25K | 78.56K | 3.70M | 4.97M |
| Inventory | - | 48.13K | - | 21.22K | 44.33K | 257.13K |
| Receivables | - | 174.40K | - | 73.17K | 244.62K | 195.70K |
| Total Liabilities | - | 7.05M | 2.30M | 1.91M | 2.69M | 3.00M |
| Current Liabilities | - | 6.98M | 2.26M | 1.89M | 2.43M | 2.79M |
| Long Term Debt | 51.69K | - | - | - | - | - |
| Total Debt | - | 598.82K | - | 224.26K | 473.40K | 416.61K |
| Total Equity | - | -5.57M | -1.06M | -1.40M | 2.07M | 3.40M |
| Shares Outstanding | - | 6.04M | - | 6.51M | 6.99M | 10.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -2.30M | -6.69M | -6.10M | -6.43M |
| Investing Cash Flow | - | -61.20K | -71.78K | -27.78K | -131.15K |
| Financing Cash Flow | - | 2.29M | 6.59M | 9.74M | 7.83M |
| Capital Expenditure | - | -61.20K | -71.78K | -27.78K | -131.15K |
| Free Cash Flow | - | -2.36M | -6.77M | -6.13M | -6.56M |
| Net Change in Cash | - | -67.16K | -175.14K | 3.62M | 1.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 88.9% | 87.7% | 86.5% | 84.2% |
| Operating Margin % | - | -125.6% | -270.9% | -266.5% | -219.4% |
| Net Margin % | - | -178.0% | -594.6% | -306.8% | -218.5% |
| ROE % | - | 85.8% | 1,042.4% | -398.6% | -229.5% |
| ROCE % | - | 61.3% | 484.3% | -307.9% | -216.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 4.14% | 519.94K | $3.96M |
| 2 | Rosalind Advisors, Inc. | 4.05% | 508.06K | $3.87M |
| 3 | Vanguard Capital Management LLC | 2.67% | 335.79K | $2.56M |
| 4 | Money Concepts Capital Corporation | 1.82% | 228.03K | $1.74M |
| 5 | Renaissance Technologies, LLC | 1.35% | 169.40K | $1.29M |
| 6 | Marshall Wace LLP | 1.03% | 128.75K | $979.83K |
| 7 | Parsons Capital Management Inc/RI | 0.94% | 117.81K | $896.52K |
| 8 | Panoramic Capital, LLC | 0.92% | 115.00K | $875.15K |
| 9 | Geode Capital Management, LLC | 0.77% | 96.36K | $733.31K |
| 10 | Citadel Advisors Llc | 0.68% | 85.05K | $647.25K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NRXS
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up
NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
Neuraxis Inc (NRXS) (Q2 2026) Earnings Call Highlights: Revenue Surges 116% as Payer Coverage ...
Neuraxis Inc (NRXS) reports record Q2 growth with gross margins expanding to 85.9% while strategically investing in VA channel expansion and large payer negotiations.
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
Conference call will be held today, Tuesday, August 11 at 9:00 am ETCARMEL, Ind., Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodul…
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y
NRXS' first-quarter 2026 results show surging revenue and expanding gross margin as reimbursement improves under the Category I CPT code.
Neuraxis Inc (NRXS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Coverage Challenges
Neuraxis Inc (NRXS) reports significant revenue growth and strategic expansions, while navigating insurance coverage hurdles and financial adjustments.
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in chi…
NRXS — Frequently Asked Questions
What is the current share price of NeurAxis, Inc. (NRXS)?
As of 2026-09-19 21:16 PDT, NeurAxis, Inc. (NRXS) trades at $5.91 on NYSE American. Its 52-week range is $2.31 to $8.81.
What is the market capitalisation of NRXS?
NeurAxis, Inc. (NRXS) has a market capitalisation of $74.22M on NYSE American.
What is the P/E ratio of NRXS?
NRXS trades at a trailing price-to-earnings (P/E) ratio of -7.78. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 14.09.
What is the return on equity (ROE) of NRXS?
NRXS has a return on equity (ROE) of -139.76%.
Is NRXS a good stock to buy?
This page provides a data-driven analysis of NeurAxis, Inc. (NRXS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.